Supporting Organizations

The ATTRACT Trial is sponsored by the National Heart Lung and Blood Institute via grants U01-HL088476 (to the Clinical Coordinating Center at Washington University in St. Louis) and U01-HL088018 (to the Data Coordinating Center at McMaster University in Hamilton, Ontario).

The following companies are providing additional support for the ATTRACT Study:

Covidien/Bacchus Vascular is a global healthcare products company that creates innovative medical solutions to improve patient outcomes. Covidien/Bacchus Vascular manufactures and distributes the Trellis Peripheral Infusion System, which can be used to deliver thrombolytic drugs to the peripheral vasculature. Covidien/Bacchus is providing supplemental funding for the ATTRACT Trial.

Genentech is considered the founder of the biotechnology industry and has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Genentech manufactures and distributes the thrombolytic drug Activase (recombinant tissue plasminogen activator). Genentech is donating Activase to be used off-label as the Study Drug in the ATTRACT Trial under an IND from the FDA.

JOBST®, a brand of BSN Medical is a global medical device company, and one of the world’s leading suppliers in the product segments of casting, bandaging, wound care and compression stockings. BSN Medical is donating Jobst elastic compression stockings for use as part of standard care in ATTRACT Trial patients.

Boston Scientific Corporation focuses on advancing interventional medicine through research and innovation. Bayer Healthcare manufactures and distributes the AngioJet Rheolytic Thrombectomy System, which can deliver thrombolytic drugs to and remove thrombus from the venous system. Boston Scientific Corporation is providing supplemental funding for the ATTRACT Trial.

We thank these partners for their vision and generosity in supporting
the
ATTRACT Trial!